Pharmacogenomic Testing in Current Clinical Practice (eBook)
XVI, 272 Seiten
Humana Press (Verlag)
978-1-60761-283-4 (ISBN)
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.
Part 1. Basic concepts Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice. Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. WuChapter 2. Molecular Diagnostic Methods in Pharmacogenomics Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. YeoChapter 3. Economics of pharmacogenomic testing in clinical practice Alan H.B. WuChapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice SystemSteven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo. Part 2. Specific pharmacogenomic targets: ChemotherapeuticsChapter 5. IrinotecanR. Stephanie Huang, Federico Innocenti and Mark J. RatainChapter 6. Pharmacogenomics of tamoxifen Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman Chapter 7. ThiopurinesTerreia S. Jones, Mary V. Relling Part 3. Specific pharmacogenomic targets: Cardiovascular drugsChapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation DrugsCharles EbyChapter 9. Clopidogrel and SalicylatesJanice Y Chyou, Marc S SabatineChapter 10. DNA-Guided Statin TherapyGualberto Ruaño, Richard L. Seip, Jorge DucongeChapter 11. The statin response gene: Kif6....................... H. Robert Superko, Tom White, James Forrester, Spencer King III. Part 4. Drugs that cause delayed hypersensitivityChapter 12. AbacavirElizabeth J. Phillips, Simon A. MallalChapter 13. AllopurinolPei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong ChenChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5........ Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping WangSteven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo. Part 2. Specific pharmacogenomic targets: ChemotherapeuticsChapter 5. IrinotecanR. Stephanie Huang, Federico Innocenti and Mark J. RatainChapter 6. Pharmacogenomics of tamoxifen Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman Chapter 7. ThiopurinesTerreia S. Jones, Mary V. Relling Part 3. Specific pharmacogenomic targets: Cardiovascular drugsChapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation DrugsCharles EbyChapter 9. Clopidogrel and SalicylatesJanice Y Chyou, Marc S SabatineChapter 10. DNA-Guided Statin TherapyGualberto Ruaño, Richard L. Seip, Jorge DucongeChapter 11. The statin response gene: Kif6....................... H. Robert Superko, Tom White, James Forrester, Spencer King III. Part 4. Drugs that cause delayed hypersensitivityChapter 12. AbacavirElizabeth J. Phillips, Simon A. MallalChapter 13. AllopurinolPei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong ChenChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5........ Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping WangChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5........ Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping Wang
Erscheint lt. Verlag | 8.2.2011 |
---|---|
Reihe/Serie | Molecular and Translational Medicine | Molecular and Translational Medicine |
Zusatzinfo | XVI, 272 p. |
Verlagsort | Totowa |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Studium ► 2. Studienabschnitt (Klinik) ► Pathologie | |
Schlagworte | Clinical Pharmacogenomics • Irinotecan • Molecular Medicine • Personalized medicine • Tamoxefin • Translational Medicine |
ISBN-10 | 1-60761-283-6 / 1607612836 |
ISBN-13 | 978-1-60761-283-4 / 9781607612834 |
Haben Sie eine Frage zum Produkt? |
Größe: 6,2 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich